Swiftmerge Acquisition Total Current Assets 2022-2024 | IVCP

Swiftmerge Acquisition total current assets from 2022 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.

Swiftmerge Acquisition Total Current Assets 2022-2024 | IVCP

Swiftmerge Acquisition total current assets from 2022 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$86.1B
Takeda Pharmaceutical (TAK)$45.9B
Merck (MKGAF)$21.6B
Astellas Pharma (ALPMY)$21.1B
Sandoz Group AG (SDZNY)$17.8B
United Therapeutics (UTHR)$15.8B
Summit Therapeutics (SMMT)$13.8B
Shionogi (SGIOY)$12.6B
Neurocrine Biosciences (NBIX)$11.5B
Catalent (CTLT)$11B
Orion OYJ (ORINY)$8B
Jazz Pharmaceuticals (JAZZ)$6.8B
Ionis Pharmaceuticals (IONS)$5.5B
Hikma Pharmaceuticals Plc (HKMPF)$5.5B
Corcept Therapeutics (CORT)$4.7B
Madrigal Pharmaceuticals (MDGL)$4.5B
Crinetics Pharmaceuticals (CRNX)$4.3B
Dyne Therapeutics (DYN)$3.3B
PTC Therapeutics (PTCT)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.4B
Arrowhead Pharmaceuticals (ARWR)$2.3B
Soleno Therapeutics (SLNO)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.8B
Recursion Pharmaceuticals (RXRX)$1.7B
NewAmsterdam Pharma (NAMS)$1.6B
Ardelyx (ARDX)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Ocular Therapeutix (OCUL)$1.5B